Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: teevee	6/6/2007 10:09:53 AM
	of 631

Isotechnika receives approval from Polish competent authority for pivotal Phase 3 psoriasis clinical trial EDMONTON, Jun 6, 2007 (Canada NewsWire via COMTEX News Network) -- Trades on Toronto Stock Exchange - (TSX:ISA) www.isotechnika.com Isotechnika Inc. announced today that the Company received approval from the Polish Competent Authority for participation in the ongoing Phase 3 European/Canadian clinical trial. This trial investigates the use of ISA247 in patients suffering from moderate to severe psoriasis. The Company previously received approval from the German Competent Authority and Health Canada to commence the trial. At present, a total of 283 patients have been enrolled in Germany and Canada. "The addition of twelve clinical trial sites in Poland allows others to gain experience with ISA247 for the treatment of psoriasis and further broadens our investigator base. Addition of these sites, to the twenty-nine sites already established in Germany and Canada, should facilitate us meeting our expected recruitment timelines for this trial," stated Dr. Randall Yatscoff, Isotechnika's President & CEO. "Patient enrolment in Poland is expected to commence immediately." Phase 3 European/Canadian Trial Design -------------------------------------- The Phase 3 European/Canadian psoriasis trial (ESSENCE) will be performed at forty-one clinical centers in Canada, Germany, and Poland. The 24-week trial is being conducted as a randomized, orally administered placebo and cyclosporine controlled trial. To maximize the benefit to patients enrolled in the placebo group, all patients randomized to the placebo group will receive active treatment with ISA247 beginning after 12 weeks of placebo dosing. To determine successful completion of the trial, the following efficacy parameters will be measured: Static Physician's Global Assessment (SPGA) scores, Psoriasis Area and Severity Index (PASI) scores. Safety parameters will also be monitored by measuring the prevalence of adverse events, including altered kidney function.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next